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710Objective: Living-donor lobar lung transplantation usually requires 2 healthy donors who donate either a right
or a left lower lobe; however, finding 2 healthy donors is difficult. Several case reports have been published on
successful living-donor lobar lung transplantation using a single donor; however, little is known about its out-
come.
Methods:We retrospectively investigated 14 critically ill patients who had undergone single living-donor lobar
lung transplantation at 3 lung transplant centers in Japan. There were 10 female and 4male patients, including 10
children and 4 adults. Size matching was assessed by estimated graft forced vital capacity and 3-dimensional
computed tomography volumetry. The diagnoses included complications of allogeneic hematopoietic stem
cell transplantation (n ¼ 6), pulmonary hypertension (n ¼ 4), and others (n ¼ 4).
Results: At a mean follow-up of 45 months (range, 2-128), the 3- and 5-year survival rate was 70% and 56%,
respectively. There were 4 early deaths, for a hospital mortality of 29%, with 1 additional death at 40 months.
The main cause of early death was primary graft dysfunction, most likely related to size mismatching. The sur-
vival among these 14 patients was significantly worse than the survival in a group of 78 patients undergoing bi-
lateral living-donor lobar lung transplantation during the same period (P ¼ .044).
Conclusions: Single living-donor lobar lung transplantation provides acceptable results for sick patients who
would die soon otherwise. However, bilateral living-donor lobar lung transplantation appears to be a better op-
tion if 2 living donors are found. (J Thorac Cardiovasc Surg 2012;144:710-5)Lung transplantation has been performed successfully in
a significant number of patients affected by various lung
diseases. However, donor organ shortages continue to be
problematic with all solid organ transplantation, particu-
larly in lung transplantation. Several strategies to solve
this challenging problem have been proposed, including
marginal donors, donation after cardiac death, and living
donors. Among these strategies, living-donor lobar lung
transplantation (LDLLT) has been performed as a lifesaving
procedure in approximately 400 patients worldwide.1 Dur-
ing the past several years, LDLLT has been almost exclu-
sively performed in Japan, where the average waiting time
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The Journal of Thoracic and Cardiovascular Surghave been reported to be equal to or better than conventional
cadaveric lung transplantation.2-5
In LDLLT, the right and left lower lobes from 2 healthy
donors are implanted in the recipient in place of whole right
and left lungs. However, finding 2 blood-type compatible
donors is not easy, especially for children. Several case re-
ports have been published on successful single LDLLT,6-10
but little has been reported on the long-term follow-up in
these patients.11,12We conducted a 3-center cooperative ret-
rospective study in Japan to investigate 14 critically ill pa-
tients who had undergone single LDLLT.METHODS
The present study was a retrospective study of patients who had under-
gone single LDLLT at 3 transplant centers in Japan. From October 1998 to
November 2011, 92 LDLLTs were performed in patients with various lung
diseases. Among these, 14 patients received single LDLLT and were the
subjects of the present study. The study protocol (E-1022) was approved
by the institutional review boards of Kyoto University Hospital, Okayama
University Hospital, and Fukuoka University Hospital, where these
LDLLTs were performed.
All recipients met the criteria for conventional single lung transplanta-
tion and were thought to be too ill to survive the long wait for cadaveric
lungs. After the full assessment of the recipients and living donors, each re-
cipient and living donor provided informed consent. Each case was care-
fully reviewed and approved by the institutional lung transplant
evaluation committee.ery c September 2012
Abbreviations and Acronyms
3D-CT ¼ 3-dimensional computed tomography
FVC ¼ forced vital capacity
HSCT ¼ hematopoietic stem cell transplantation
LDLLT ¼ living-donor lobar lung transplantation
PGD ¼ primary graft dysfunction
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T
XGiven that the right lower lobe consists of 5 segments, the left lower lobe
4, and thewhole lung 19, we estimated the graft forced vital capacity (FVC)
using the following equation:
Right graft FVC ¼ measured FVC of the right donor3 5=19
Left graft FVC ¼ measured FVC of the left donor3 4=19
A size disparity was acceptable only when the FVC of the donor lobe
was 45% or more of the predicted FVC of the recipient (calculated accord-
ing to height, age, and gender).5
Three-dimensional computed tomography (3D-CT) volumetry was per-
formed for both the donor and the recipient in 11 recent single LDLLTs.
The CT images were obtained using a multidetector CT scanner during
a single respiratory pause at the end of maximum inspiratory effort.
The surgical aspects of donor lobectomy and graft implantation under
the condition of cardiopulmonary bypass have been previously described
in detail.6-10 Postoperative immunosuppression consisted of triple-drug
therapy with cyclosporine or tacrolimus, azathioprine or mycophenolate
mofetil, and corticosteroids without the use of induction cytolytic therapy.
Acute rejection was judged on the basis of radiographic and clinical find-
ings without transbronchial lung biopsy to avoid intragraft bleeding. Acute
rejection was treated with a daily bolus dose of 10 mg/kg methylpredniso-
lone for 3 days.
For all 14 patients and 14 living donors, the inpatient and outpatient
medical records were retrospectively reviewed. The survival of the 14 pa-
tients undergoing single LDLLTwas compared with that of 78 patients who
underwent bilateral LDLLT during the same period. The survival times
were calculated from the date of LDLLT. The results were analyzed as
of January 10, 2012.
Statistical Analysis
The data are presented as the mean  standard error of the mean. The
size matching data were evaluated using Student’s t test for 2-group anal-
ysis. Observed survival data are reported as Kaplan-Meier estimates; the
log-rank test was used to explore the significance of the difference between
the 2 groups.RESULTS
Recipient Characteristics
The clinical characteristics of the 14 patients undergoing
single LDLLT are listed in Table 1. The age range of the 10
female and 4 male patients was 4 to 48 years (average,
17.8). Of the 14 patients, 10 were children and 4 were
adults.
Six patients developed bronchiolitis obliterans and/or
pulmonary fibrosis as complications of allogeneic hemato-
poietic stem cell transplantation (HSCT). We confirmed
that all the patients converted to full donor chimerism. Of
these 6 patients, 3 (patients 3, 4, and 9) received a lobeThe Journal of Thoracic and Cafrom the same living-donor as for HSCT. The diagnoses
for HSCT included myelodysplastic syndrome (patients 2
and 7), acute myelomonocytic leukemia (patient 3), acute
lymphatic leukemia (patient 4), primary macroglobuline-
mia (patient 9), and severe combined immunodeficiency
(patient 12). The mean interval between HSCT and single
LDLLT was 54.8 months (range, 9-129 months). One pa-
tient (patient 2) had an interval of less than 2 years, but
the relapse rate of the original hematopoietic disorder was
estimated to be less than 20% by expert hematologists.
Four patients were diagnosed with pulmonary hyperten-
sion, resulting from pulmonary veno-occlusive disease
(n ¼ 2), idiopathic pulmonary arterial hypertension
(n ¼ 1), and repaired transposition of the great arteries
(n ¼ 1). Other diagnoses were lymphangioleiomyomatosis
(n ¼ 1), bronchiolitis obliterans after Steven-Johnson syn-
drome (n ¼ 1), idiopathic pulmonary fibrosis (n ¼ 1), and
pulmonary fibrosis caused by chemotherapy for breast can-
cer (n ¼ 1).
All patients were hospital bound and were dependent on
continuous oxygen inhalation. Of the 14 patients, 4 (pa-
tients 3, 6, 7 and 13) required a ventilator at single LDLLT.
Donor Characteristics
Among the 14 living donors, 9 were the mothers of the
recipients, 3 were husbands, 1 was a father, and 1 was a sis-
ter, with an age range of 28 to 49 years (average, 38.0
years).
Surgical Procedure
Of the 14 patients, 7 patients underwent single LDLLTat
Kyoto University, 4 at Okayama University, and 3 at Fu-
kuoka University.
Thirteen of 14 patients received a right single LDLLTand
1 (patient 3) received a left single LDLLT. Three patients
(patients 2, 7, and 12) undergoing right single LDLLT re-
quired simultaneous left pneumonectomy to provide more
space for the oversized graft, with the expectation that the
mediastinum would shift toward the left. In 3 additional pa-
tients (patients 10, 13, and 14), the chest was temporarily
closed without rib approximation owing to the oversized
graft. Delayed chest closurewas performed on day 1 in 2 pa-
tients and day 17 in 1 patient.
One patient (patient 12) with a funnel chest had an ex-
tremely small chest cavity and required graft downsizing
by removal of the superior segment of the oversized right
lower lobe graft. The removed segment was then implanted
as a left graft after left pneumonectomy. The left graft be-
came congestive, and graftectomy was performed on day 1.
We did not downsize the donor lobe in any other patient.
One patient (patient 14) undergoing right single LDLLT
required a left single LDLLTon day 17 because of progres-
sive graft dysfunction. Massive airway bleeding without
a detectable cause occurred immediately after reperfusion.rdiovascular Surgery c Volume 144, Number 3 711








17,11 10 y, M IPAH WHO 3 38 y, F, mother R single-lobe Tx
223 6 y, F BO/PF after HSCT H-J 5 35 y, F, mother R single-lobe Tx, left pneumonectomy
310,12,23 4 y, M BO after HSCT Ventilator for 4 wk 28 y, F, mother L single-lobe Tx
423 13 y, M BO after HSCT H-J 5 34 y, F, mother R single-lobe Tx
5 30 y, F LAM H-J 4 30 y, M, husband R single-lobe Tx
68 6 y, F BO after SJS Ventilator for 7 mo 35 y, F, mother R single-lobe Tx
79,23 8 y, F BO/PF after HSCT Ventilator for 11 wk 33 y, F, mother R single-lobe Tx, left pneumonectomy
8 43 y, F PVOD WHO 4 44 y, M, husband R single-lobe Tx
923 41 y, F BO after HSCT H-J 5 39 y, F, sister R single-lobe Tx
10 6 y, F IPF H-J 5 44 y, F, mother R single-lobe Tx, delayed chest closure (1 POD)
11 48 y, F PF after chemotherapy H-J 5 49 y, M, husband R single-lobe Tx
12 11 y, M BO/PF after HSCT
funnel chest
H-J 5 46 y, F, mother R single-lobe Tx, graft S6 segmentectomy, left
pneumonectomy
13 6 y, F PVOD Ventilator for 5 d 38 y, F, mother R single-lobe Tx, delayed chest closure (1 POD)
14 12 y, F Repaired TGAþPH WHO 4 39 y, M, father R single-lobe Tx, delayed chest closure (13 POD),
L single-lobe Tx (17 POD)
Pt. no., Patient number;M,male; IPAH, idiopathic pulmonary arterial hypertension;WHO, World Health Organization; F, female; R, right; Tx, transplantation; BO, bronchiolitis
obliterans; PF, pulmonary fibrosis; HSCT, hematopoietic stem cell transplantation; H-J, Hugh-Jones; L, left; LAM, lymphangioleiomyomatosis; SJS, Steven-Johnson syndrome;
PVOD, pulmonary veno-occlusive disease; IPF, idiopathic pulmonary fibrosis; POD, postoperative day; TGA, transposition of the great arteries; PH, pulmonary hypertension.
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T
XLeft graft function was lost, and left graftectomy was
required.
Size Matching and Primary Graft Dysfunction
The size matching data are listed in Table 2. The recipient
height ranged from 98 to 163 cm (average, 124.5 cm), and
the weight ranged from 12.4 to 58 kg (average, 24.7 kg).
The donor height ranged from 153 to 182 cm (average,
164.4 cm), and the weight ranged from 45.1 to 90.5 kg (av-
erage, 60.4 kg).
The estimated graft FVC (according to the donor’s mea-















1 10 y, M 122.7, 20.4 158, 52 52.3 NA
2 6 y, F 106, 18.5 160, 48.5 79.4 NA
3 4 y, M 98, 13 159.5, 55 78.0 118
4 13 y, M 125, 16 167, 51.5 47.3 119
5 30 y, F 153.3, 47 178.0, 76 53.0 NA
6 6 y, F 113, 15.4 160, 58 73.3 161
7 8 y, F 111, 12.4 162, 68 67.0 200
8 43 y, F 163, 58 182, 95.9 55.8 88
9 41 y, F 128, 32.1 164.5, 58.2 45.1 80
10 6 y, F 105, 13.4 163, 55 90.5 207
11 48 y, F 156, 37 171, 70 54.4 207
12 11 y, M 125.2, 16.9 164, 53.3 50.7 395
13 6 y, F 109, 16 153, 40 78.9 173
14 12 y, F 127.7, 29 160, 64 57.0 179
Pt. no., Patient number; FVC, forced vital capacity; CT, computed tomography; PGD, p
NA, not assessed; H-J, Hugh-Jones; F, female; ICU, intensive care unit.
712 The Journal of Thoracic and Cardiovascular Surg1009  80 mL (range, 503-1587 mL). Compared with the
recipient predicted FVC, the graft FVC was 63.1% 
4.0% (range, 47.3-90.5%).
The graft volume measured using 3D-CT volumetry was
1300 110 mL (range, 676-1906 mL). The recipient hemi-
thorax volume was 914  175 mL (range, 338-2148 mL).
The graft volume/recipient hemithorax volume ratio was
175%  27% (range, 80.5-395%).
Severe primary graft dysfunction (PGD) requiring extra-
corporeal membrane oxygenation occurred in 4 patients
(patients 8, 11, 12, and 14). Size matching data were com-











0 10 y, 8 mo, alive H-J 2
0 61 d, died Aspergillosis
0 5 y, 2 mo, alive H-J 1
0 3 y, 4 mo, died Unknown
0 4 y, 5 mo, alive H-J 1
0 3 y, 7 mo, alive H-J 2
0 3 y, 3 mo, alive H-J 2
.7 3, ECMO 103 d, died PGD, sepsis
.5 0 3 y, 2 mo, alive H-J 2
0 1 y, 6 mo, alive H-J 1
3, ECMO 10 d, died PGD
3, ECMO 14 d, died PGD
0 6 mo, alive H-J 1
3, ECMO 2 mo, alive in ICU
rimary graft dysfunction; ECMO, extracorporeal membrane oxygenation; M, male;
ery c September 2012
FIGURE 1. A, Forced vital capacity (FVC) size matching. Graft FVC was 66.5% 5.0% in non-primary graft dysfunction (PGD) patients and 54.5%
1.4% in PGD patients (P¼ .169). Note, all 4 PGD patients had graft FVC of 60% or less. B, Three-dimensional computed tomography (3D-CT) size match-
ing. The graft volume/recipient hemithorax volume ratio measured using 3D-CT volumetry was 151.2%  17.7% in non-PGD patients and 217.4% 
64.4% in PGD patients (P¼ .238). Note, all 6 patients who had a volume ratio of170% required additional procedures, such as extracorporeal membrane
oxygenation (ECMO) support for severe PGD, delayed chest closure, or left pneumonectomy.
Date et al Cardiothoracic TransplantationThe graft FVC was 66.5%  5.0% in the non-PGD pa-
tients and 54.5%  1.4% in the PGD patients (P ¼ .169;
Figure 1, A). All 4 PGD patients had a graft FVC of 60%
or less.
The graft volume/recipient hemithorax volume ratio, as
measured using 3D-CT volumetry, was 151.2%  17.7%
in the non-PGD patients and 217.4%  64.4% in the
PGD patients (P ¼ .238; Figure 1, B). All 6 patients with
a ratio of 170% or greater required additional procedures
such as extracorporeal membrane oxygenation support for
severe PGD (n ¼ 3), delayed chest closure (n ¼ 2), or left
pneumonectomy (n ¼ 1).
Figure 2 illustrates the association between the FVC size
matching and the 3D-CT size matching. All 3 patients who
had graft FVC of 60% or less and 3D-CT volume of 170%
or greater developed severe PGD.FIGURE 2. The association between forced vital capacity (FVC) size
matching and 3-dimensional computed tomography (3D-CT) size match-
ing. Note, all 3 patients who had graft FVC of 60% or less and a 3D-CT
volume ratio of 170% or more developed severe primary graft dysfunction
(PGD) requiring extracorporeal membrane oxygenation (ECMO) support.
The Journal of Thoracic and CaRecipient Outcome
There were 4 early deaths, for a hospital mortality of
29%. Three patients (patients 8, 11, and 12) died of
PGD 10 to 103 days after transplantation. One patient (pa-
tient 2) died of aspergillosis (Aspergillus tereus) on day 61,
although the early postoperative course had been unevent-
ful. One additional patient (patient 4) died at 40 months;
the patient was found dead in the morning of an unknown
cause.
At the final data analysis on January 10, 2012, the mean
interval from single LDLLT to the final analysis for the 14
patients was 45months (range, 2-128months). The 1, 3, and
5 year survival for the 14 recipients was 70%, 70%, and
56%, respectively. The survival among the 14 patients un-
dergoing single LDLLTwas significantly worse than that of
a group of 78 patients who underwent bilateral LDLLT dur-
ing the same period (P ¼ .044; Figure 3).FIGURE 3. Actuarial survival after single living-donor lobar lung trans-
plantation (LDLLT) (n ¼ 14) compared with that after bilateral LDLLT
(n¼ 78). Bilateral LDLLT provided significantly better survival than single
LDLLT (P ¼ .044).
rdiovascular Surgery c Volume 144, Number 3 713
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XOf the 9 currently surviving recipients, bronchiolitis ob-
literans syndrome occurred in 2 patients at 84 (patient 1)
and 24 (patient 6) months. By increasing immunosuppres-
sion, the forced expiratory volume in 1 second for these 2
patients reached a plateau within 6 months. Except for 1 pa-
tient who had recently undergone single LDLLT, all 8 sur-
vivors were able to perform daily activities without
oxygen inhalation with a Hugh-Jones I (n ¼ 4) or II
(n ¼ 4) classification. The percentage of FVC was 61.3%
 4.2%, and the 6-minute walking distance was 407 
25 m at 6 to 12 months.
Donor Outcome
No significant operative morbidity occurred with donor
lobectomy, except that 1 donor developed mild temporary
hemosputum. All 14 donors returned to their previous life-
styles during the observation period.
DISCUSSION
LDLLTwas introduced by Starnes and colleagues13 as an
alternative form of treatment for patients with a decline in
physical conditionwith a limited life expectancy. The first pa-
tient was an 11-year-old girl with bronchopulmonary dyspla-
sia. In 1990, she underwent right single LDLLT using the
right upper lobe of her mother and survived. The second pa-
tient was a 3-year-girl with Eisenmenger syndrome. She un-
derwent right single LDLLT using the middle lobe of her
father plus ventricular septal defect closure; however, she
died of PGD that developed immediately after reperfusion.
After the unsuccessful result in the second case, they devel-
oped bilateral LDLLTinwhich 2 healthy donors donated their
right or left lower lobes.14,15 Since then, bilateral LDLLT has
been performed worldwide as a lifesaving procedure. The
results of bilateral LDLLT have been equal to or better than
conventional cadaveric lung transplantation.2-5
We accept only immediate family members (relatives
within the third degree or a spouse) as living donors, and
their ABO blood type must be compatible with that of the
recipient. With these donor selection criteria, finding 2 suit-
able living donors is not easy. We, and others, have reported
anecdotal successful single LDLLT6-12; however, the results
of a single LDLLT series have never been reported. Because
each transplant center has a quite limited number of single
LDLLT cases, a 3-center cooperative study was conducted.
We believe that the present study cohort of 14 patients un-
dergoing single LDLLT represents more than 70% of the
worldwide experience with this rare procedure.
Because only 1 lobe is implanted in single LDLLT, ap-
propriate size matching between the donor and recipient
is extremely important. When the lobe is too small for the
recipient, pulmonary edemawill develop in the transplanted
single lobe because a preponderance of pulmonary flowwill
be directed to the transplanted lobe as a result of greater pul-
monary vascular resistance in the remaining diseased native714 The Journal of Thoracic and Cardiovascular Surglung.16 When the lobe is too large for the hemithorax of the
recipient, it will cause high airway resistance, atelectasis,
and hemodynamic instability at chest closure.17
For ‘‘functional size matching,’’ we used the percentage
of graft FVC. It has been used to determine the lowest
threshold (45%) for undersized grafts.5,18 For ‘‘anatomic
size matching’’, 3D-CT volumetry has recently been
introduced.19,20 It was reported to be useful in evaluating
oversized grafts21; however, an upper threshold has not
yet been determined.
Four patients (29%) developed severe PGD, resulting in
extracorporeal membrane oxygenation support, and PGD
was found to be the major cause of early mortality after sin-
gle LDLLT. However, the remaining 10 patients (71%), in-
cluding 2 patients who underwent simultaneous left
pneumonectomy, were weaned off bypass without develop-
ing PGD.10
As shown in Figure 1, A, all 4 PGD patients had a graft
FVC of 60% or less. However, it should also be noted
that 4 other patients with a graft FVC of 60% or less had
an uneventful postoperative course. Figure 1, B, shows
that 3 of 4 PGD patients had a graft 3D-CT volume of
170% or more. Although 3 non-PGD patients also had
a 3D-CT volume ratio of 170% or more, they all required
additional procedures, such as left pneumonectomy or de-
layed chest closure. We found combining ‘‘functional size
matching’’ and ‘‘anatomic size matching’’ to be of great im-
portance for single LDLLT (Figure 2). All 3 patients who
had a graft FVC of 60% or less and a 3D-CT volume ratio
of 170% or greater developed severe PGD, suggesting that
a lobe that is ‘‘small for the body but large for the chest cav-
ity’’ should not be implanted.
Although the hospital mortality rate was relatively high,
the intermediate-term survival after single LDLLT was en-
couraging. The overall actuarial survival of 70%, 70%, and
56% at 1, 3, and 5 years, respectively, was comparable to
that for reported cadaveric lung transplantation from the In-
ternational Society for Heart and Lung Transplantation
Registry (79%, 64%, and 53%, respectively).22 Bronchio-
litis obliterans syndrome has been the major obstacle after
cadaveric lung transplantation. However, bronchiolitis ob-
literans syndrome was seen in only 2 recipients and was
not a cause of death in the present study cohort. Three pa-
tients who received a lobe from the same donor as for pre-
vious HSCT required no or minimal immunosuppression
without developing rejection.23 With only 1 lobe trans-
planted, the survivors have been able to perform daily activ-
ities and to attend school. Knowing that the preoperative
condition of our patients was very poor, with 100% hospital
bound and 29% ventilator dependent, single LDLLT pro-
vided acceptable intermediate results for very ill patients
whose life expectancy was quite limited.
A number of studies have reported that bilateral lung
transplantation provides better long-term survival thanery c September 2012
Date et al Cardiothoracic Transplantationsingle lung transplantation.22,24,25 Likewise, the survival of
90%, 84%, and 82% at 1, 3, and 5 years, respectively, after
bilateral LDLLT was better than that after single LDLLT.
When 2 suitable living donors are found, bilateral LDLLT
is certainly a better option.
CONCLUSIONS
The present 3-center cooperative study showed that sin-
gle LDLLT provides acceptable intermediate results for
sick patients when only 1 suitable living donor is available.
Size matching is very important, and graft FVC and 3D-CT
volumetry provide useful information for this. A lobe that is
small for the body but large for the chest cavity should not
be used. Bilateral LDLLT is a better option if 2 living do-
nors can be found.
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